Comprehensive genomic and immune profiling of invasive breast cancers, including a lobular-enriched cohort and non-lobular cohort, revealed that lobular-enriched tumors had distinct molecular and immunologic characteristics.

The study shows that tumor tissues collected in vivo had a higher tumor immunogenicity signature and lower cellular proliferation signature compared to cell lines grown in culture, indicating that an active immune system and a vascularized environment contribute to decreased cancer cell proliferation.

ALK-positive lung adenocarcinomas are associated with a younger age at sequencing, lower tumor mutational burden, higher PD-L1 expression, and lower cancer testis antigen burden compared to ALK-wild-type, EGFR mutated, and KRAS

Distinct genomic alterations were identified in different gene expression and immunotherapy marker defined immune-response phenotypes, with tumor-dominant phenotype tumors having the highest number of enriched alterations.

Tumors of younger patients with NSCLC had distinct genomic profiles with more targetable alterations, but lower mutational burden and immunogenicity compared to older patient tumors.

The study found that brain metastases in melanoma had a weaker immune response compared to primary skin, lymph node, and other metastatic sites, suggesting reduced immune cell infiltration and expression of immune checkpoint inhibitor targets.

Metastatic triple-negative breast cancer (TNBC) exhibits increased inflammation and higher expression of checkpoint targets compared to non-TNBC cases, with a paradoxical finding that lower PD-L1 expression is associated with better overall survival.